首页 > 最新文献

JAMA surgery最新文献

英文 中文
Error in Byline and Open Access Status. 署名和开放访问状态中出现错误。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2025-01-02 DOI: 10.1001/jamasurg.2024.6489
{"title":"Error in Byline and Open Access Status.","authors":"","doi":"10.1001/jamasurg.2024.6489","DOIUrl":"https://doi.org/10.1001/jamasurg.2024.6489","url":null,"abstract":"","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":""},"PeriodicalIF":15.7,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JAMA Surgery. JAMA手术。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2025-01-01 DOI: 10.1001/jamasurg.2024.4420
{"title":"JAMA Surgery.","authors":"","doi":"10.1001/jamasurg.2024.4420","DOIUrl":"https://doi.org/10.1001/jamasurg.2024.4420","url":null,"abstract":"","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":"160 1","pages":"4"},"PeriodicalIF":15.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. 胰腺腺癌切除术后的常规成像或症状随访。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2025-01-01 DOI: 10.1001/jamasurg.2024.5024
Paul C M Andel, Iris W J M van Goor, Simone Augustinus, Frederik Berrevoet, Marc G Besselink, Rajesh Bhojwani, Ugo Boggi, Stefan A W Bouwense, Geert A Cirkel, Jacob L van Dam, Angela Djanani, Dimitri Dorcaratto, Stephan Dreyer, Marcel den Dulk, Isabella Frigerio, Poya Ghorbani, Mara R Goetz, Bas Groot Koerkamp, Filip Gryspeerdt, Camila Hidalgo Salinas, Martijn Intven, Jakob R Izbicki, Rosa Jorba Martin, Emanuele F Kauffmann, Reinhold Klug, Mike S L Liem, Misha D P Luyer, Manuel Maglione, Elena Martin-Perez, Mark Meerdink, Vincent E de Meijer, Vincent B Nieuwenhuijs, Andrej Nikov, Vitor Nunes, Elizabeth Pando, Dejan Radenkovic, Geert Roeyen, Francisco Sanchez-Bueno, Alejandro Serrablo, Ernesto Sparrelid, Konstantinos Tepetes, Rohan G Thakkar, George N Tzimas, Robert C Verdonk, Meike Ten Winkel, Alessandro Zerbi, Vincent P Groot, I Quintus Molenaar, Lois A Daamen, Hjalmar C van Santvoort

Importance: International guidelines lack consistency in their recommendations regarding routine imaging in the follow-up after pancreatic resection for pancreatic ductal adenocarcinoma (PDAC). Consequently, follow-up strategies differ between centers worldwide.

Objective: To compare clinical outcomes, including recurrence-focused treatment and survival, in patients with PDAC recurrence who received symptomatic follow-up or routine imaging after pancreatic resection in international centers affiliated with the European-African Hepato-Pancreato-Biliary Association (E-AHPBA).

Design, setting, and participants: This was a prospective, international, cross-sectional study. Patients from a total of 33 E-AHPBA centers from 13 countries were included between 2020 and 2021. According to the predefined study protocol, patients who underwent PDAC resection and were diagnosed with disease recurrence were prospectively included. Patients were stratified according to postoperative follow-up strategy: symptomatic follow-up (ie, without routine imaging) or routine imaging.

Exposures: Symptomatic follow-up or routine imaging in patients who underwent PDAC resection.

Main outcomes and measures: Overall survival (OS) was estimated with Kaplan-Meier curves and compared using the log-rank test. To adjust for potential confounders, multivariable logistic regression was used to evaluate the association between follow-up strategy and recurrence-focused treatment. Multivariable Cox proportional hazard analysis was used to study the independent association between follow-up strategy and OS.

Results: Overall, 333 patients (mean [SD] age, 65 [11] years; 184 male [55%]) with PDAC recurrence were included. Median (IQR) follow-up at time of analysis 2 years after inclusion of the last patient was 40 (30-58) months. Of the total cohort, 98 patients (29%) received symptomatic follow-up, and 235 patients (71%) received routine imaging. OS was 23 months (95% CI, 19-29 months) vs 28 months (95% CI, 24-30 months) in the groups who received symptomatic follow-up vs routine imaging, respectively (P = .01). Routine imaging was associated with receiving recurrence-focused treatment (adjusted odds ratio, 2.57; 95% CI, 1.22-5.41; P = .01) and prolonged OS (adjusted hazard ratio, 0.75; 95% CI, 0.56-.99; P = .04).

Conclusion and relevance: In this international, prospective, cross-sectional study, routine follow-up imaging after pancreatic resection for PDAC was independently associated with receiving recurrence-focused treatment and prolonged OS.

重要性:国际指南对胰腺导管腺癌(PDAC)胰腺切除术后随访的常规成像建议缺乏一致性。因此,全球不同中心的随访策略也不尽相同:目的:比较欧洲-非洲肝胰胆协会(E-AHPBA)下属国际中心胰腺切除术后接受无症状随访或常规影像学检查的 PDAC 复发患者的临床结果,包括以复发为重点的治疗和生存率:这是一项前瞻性国际横断面研究。2020年至2021年期间,共有来自13个国家的33个E-AHPBA中心的患者参与了研究。根据预先确定的研究方案,前瞻性纳入了接受PDAC切除术并确诊为疾病复发的患者。根据术后随访策略对患者进行分层:无症状随访(即无常规影像学检查)或常规影像学检查:主要结果和测量指标:用卡普兰-梅耶曲线估算总生存期(OS),并用对数秩检验进行比较。为调整潜在的混杂因素,采用多变量逻辑回归评估随访策略与复发重点治疗之间的关系。多变量 Cox 比例危险分析用于研究随访策略与 OS 之间的独立关联:共纳入 333 例 PDAC 复发患者(平均 [SD] 年龄 65 [11] 岁;184 例男性 [55%])。最后一名患者入组 2 年后进行分析时的随访中位数(IQR)为 40 (30-58) 个月。在所有患者中,98 名患者(29%)接受了症状随访,235 名患者(71%)接受了常规影像学检查。接受症状随访组和常规成像组的OS分别为23个月(95% CI,19-29个月)和28个月(95% CI,24-30个月)(P = .01)。常规成像与接受以复发为重点的治疗(调整后的几率比为2.57;95% CI为1.22-5.41;P = .01)和延长OS(调整后的危险比为0.75;95% CI为0.56-.99;P = .04)有关:在这项国际性前瞻性横断面研究中,PDAC胰腺切除术后常规随访成像与接受以复发为重点的治疗和延长OS有独立关联。
{"title":"Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma.","authors":"Paul C M Andel, Iris W J M van Goor, Simone Augustinus, Frederik Berrevoet, Marc G Besselink, Rajesh Bhojwani, Ugo Boggi, Stefan A W Bouwense, Geert A Cirkel, Jacob L van Dam, Angela Djanani, Dimitri Dorcaratto, Stephan Dreyer, Marcel den Dulk, Isabella Frigerio, Poya Ghorbani, Mara R Goetz, Bas Groot Koerkamp, Filip Gryspeerdt, Camila Hidalgo Salinas, Martijn Intven, Jakob R Izbicki, Rosa Jorba Martin, Emanuele F Kauffmann, Reinhold Klug, Mike S L Liem, Misha D P Luyer, Manuel Maglione, Elena Martin-Perez, Mark Meerdink, Vincent E de Meijer, Vincent B Nieuwenhuijs, Andrej Nikov, Vitor Nunes, Elizabeth Pando, Dejan Radenkovic, Geert Roeyen, Francisco Sanchez-Bueno, Alejandro Serrablo, Ernesto Sparrelid, Konstantinos Tepetes, Rohan G Thakkar, George N Tzimas, Robert C Verdonk, Meike Ten Winkel, Alessandro Zerbi, Vincent P Groot, I Quintus Molenaar, Lois A Daamen, Hjalmar C van Santvoort","doi":"10.1001/jamasurg.2024.5024","DOIUrl":"10.1001/jamasurg.2024.5024","url":null,"abstract":"<p><strong>Importance: </strong>International guidelines lack consistency in their recommendations regarding routine imaging in the follow-up after pancreatic resection for pancreatic ductal adenocarcinoma (PDAC). Consequently, follow-up strategies differ between centers worldwide.</p><p><strong>Objective: </strong>To compare clinical outcomes, including recurrence-focused treatment and survival, in patients with PDAC recurrence who received symptomatic follow-up or routine imaging after pancreatic resection in international centers affiliated with the European-African Hepato-Pancreato-Biliary Association (E-AHPBA).</p><p><strong>Design, setting, and participants: </strong>This was a prospective, international, cross-sectional study. Patients from a total of 33 E-AHPBA centers from 13 countries were included between 2020 and 2021. According to the predefined study protocol, patients who underwent PDAC resection and were diagnosed with disease recurrence were prospectively included. Patients were stratified according to postoperative follow-up strategy: symptomatic follow-up (ie, without routine imaging) or routine imaging.</p><p><strong>Exposures: </strong>Symptomatic follow-up or routine imaging in patients who underwent PDAC resection.</p><p><strong>Main outcomes and measures: </strong>Overall survival (OS) was estimated with Kaplan-Meier curves and compared using the log-rank test. To adjust for potential confounders, multivariable logistic regression was used to evaluate the association between follow-up strategy and recurrence-focused treatment. Multivariable Cox proportional hazard analysis was used to study the independent association between follow-up strategy and OS.</p><p><strong>Results: </strong>Overall, 333 patients (mean [SD] age, 65 [11] years; 184 male [55%]) with PDAC recurrence were included. Median (IQR) follow-up at time of analysis 2 years after inclusion of the last patient was 40 (30-58) months. Of the total cohort, 98 patients (29%) received symptomatic follow-up, and 235 patients (71%) received routine imaging. OS was 23 months (95% CI, 19-29 months) vs 28 months (95% CI, 24-30 months) in the groups who received symptomatic follow-up vs routine imaging, respectively (P = .01). Routine imaging was associated with receiving recurrence-focused treatment (adjusted odds ratio, 2.57; 95% CI, 1.22-5.41; P = .01) and prolonged OS (adjusted hazard ratio, 0.75; 95% CI, 0.56-.99; P = .04).</p><p><strong>Conclusion and relevance: </strong>In this international, prospective, cross-sectional study, routine follow-up imaging after pancreatic resection for PDAC was independently associated with receiving recurrence-focused treatment and prolonged OS.</p>","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":"74-84"},"PeriodicalIF":15.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11541741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis of Respiratory Sarcopenia for Stratifying Postoperative Risk in Non-Small Cell Lung Cancer. 非小细胞肺癌术后风险分层之呼吸道肌营养不良症诊断
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2025-01-01 DOI: 10.1001/jamasurg.2024.4800
Changbo Sun, Yoshifumi Hirata, Takuya Kawahara, Mitsuaki Kawashima, Masaaki Sato, Jun Nakajima, Masaki Anraku
<p><strong>Importance: </strong>Physical biomarkers for stratifying patients with lung cancer into subtypes suggestive of outcomes are underexplored.</p><p><strong>Objective: </strong>To investigate the clinical utility of respiratory sarcopenia for optimizing postoperative risk stratification in patients with non-small cell lung cancer (NSCLC).</p><p><strong>Design, setting, and participants: </strong>This retrospective cohort study reviewed consecutive patients undergoing lobectomy and mediastinal lymph node dissection for NSCLC at 2 institutions in Tokyo, Japan, between 2009 and 2018. Eligible patients underwent electronic computed tomography image analysis. Follow-up began at the date of surgery and continued until death, the last contact, or March 2022. Data analysis was performed from April 2022 to March 2023.</p><p><strong>Main outcomes and measures: </strong>Respiratory sarcopenia was identified by poor respiratory strength (peak expiratory flow rate) and was confirmed by a low pectoralis muscle index (PMI; pectoralis muscle area/body mass index). Patients with poor peak expiratory flow rate but normal PMI received a diagnosis of pre-respiratory sarcopenia. Short-term and long-term postoperative outcomes were compared among patients with a normal status, pre-respiratory sarcopenia, and respiratory sarcopenia. Group differences were analyzed using the Kruskal-Wallis test and Pearson χ2 test for continuous and categorical data, respectively. Survival differences were compared using the log-rank test. Univariable and multivariable analyses were conducted using the Cox proportional hazards model.</p><p><strong>Results: </strong>Of a total of 1016 patients, 806 (497 men [61.7%]; median [IQR] age, 69 [64-76] years) were eligible for electronic computed tomography image analysis. The median (IQR) duration of follow-up for survival was 5.2 (3.6-6.4) years. Respiratory strength was more closely correlated with PMI than pectoralis muscle radiodensity (Pearson r2, 0.58 vs 0.29). Respiratory strength and PMI declined with aging simultaneously (both P for trend < .001). Pre-respiratory sarcopenia was present in 177 patients (22.0%), and respiratory sarcopenia was present in 130 patients (16.1%). The risk of postoperative complications escalated from 82 patients (16.4%) with normal status to 39 patients (22.0%) with pre-respiratory sarcopenia to 39 patients (30.0%) with respiratory sarcopenia (P for trend < .001), as did the risk of delayed recovery after surgery (P for trend < .001). Compared with patients with normal status or pre-respiratory sarcopenia, patients with respiratory sarcopenia exhibited worse 5-year overall survival (438 patients [87.2%] vs 133 patients [72.9%] vs 85 patients [62.5%]; P for trend < .001). Multivariable analysis identified respiratory sarcopenia as a factor independently associated with increased risk of mortality (hazard ratio, 1.83; 95% CI, 1.15-2.89; P = .01) after adjustment for sex, age, smoking status, performance
重要性:用于对肺癌患者进行亚型分层的物理生物标志物尚未得到充分探索:研究呼吸道肌肉疏松对优化非小细胞肺癌(NSCLC)患者术后风险分层的临床实用性:这项回顾性队列研究回顾了 2009 年至 2018 年间在日本东京两家医疗机构接受肺叶切除术和纵隔淋巴结清扫术治疗 NSCLC 的连续患者。符合条件的患者接受了电子计算机断层图像分析。随访从手术当日开始,直至死亡、最后一次联系或 2022 年 3 月。数据分析于2022年4月至2023年3月进行:呼吸肌疏松症通过呼吸强度(呼气峰流速)差来识别,并通过胸肌指数(PMI;胸肌面积/体重指数)低来确认。呼气峰流速较低但胸肌指数正常的患者被诊断为呼吸前肌少症。研究人员比较了状态正常、呼吸肌疏松症前期和呼吸肌疏松症患者的术后短期和长期疗效。对于连续数据和分类数据,分别采用 Kruskal-Wallis 检验和 Pearson χ2 检验分析组间差异。生存率差异采用对数秩检验进行比较。采用 Cox 比例危险度模型进行单变量和多变量分析:在总共 1016 名患者中,有 806 人(497 名男性[61.7%];中位数[IQR]年龄为 69 [64-76] 岁)符合电子计算机断层图像分析条件。生存随访时间的中位数(IQR)为 5.2(3.6-6.4)年。呼吸强度与 PMI 的相关性比胸肌放射密度更密切(Pearson r2,0.58 vs 0.29)。随着年龄的增长,呼吸强度和 PMI 同时下降(趋势结论和相关性均为 P):本研究通过对呼吸肌疏松症进行筛查和分期,确定了不良预后风险较高的人群。呼吸肌疏松症的早期诊断可优化管理策略,促进 NSCLC 患者的纵向护理。
{"title":"Diagnosis of Respiratory Sarcopenia for Stratifying Postoperative Risk in Non-Small Cell Lung Cancer.","authors":"Changbo Sun, Yoshifumi Hirata, Takuya Kawahara, Mitsuaki Kawashima, Masaaki Sato, Jun Nakajima, Masaki Anraku","doi":"10.1001/jamasurg.2024.4800","DOIUrl":"10.1001/jamasurg.2024.4800","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Physical biomarkers for stratifying patients with lung cancer into subtypes suggestive of outcomes are underexplored.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To investigate the clinical utility of respiratory sarcopenia for optimizing postoperative risk stratification in patients with non-small cell lung cancer (NSCLC).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This retrospective cohort study reviewed consecutive patients undergoing lobectomy and mediastinal lymph node dissection for NSCLC at 2 institutions in Tokyo, Japan, between 2009 and 2018. Eligible patients underwent electronic computed tomography image analysis. Follow-up began at the date of surgery and continued until death, the last contact, or March 2022. Data analysis was performed from April 2022 to March 2023.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Respiratory sarcopenia was identified by poor respiratory strength (peak expiratory flow rate) and was confirmed by a low pectoralis muscle index (PMI; pectoralis muscle area/body mass index). Patients with poor peak expiratory flow rate but normal PMI received a diagnosis of pre-respiratory sarcopenia. Short-term and long-term postoperative outcomes were compared among patients with a normal status, pre-respiratory sarcopenia, and respiratory sarcopenia. Group differences were analyzed using the Kruskal-Wallis test and Pearson χ2 test for continuous and categorical data, respectively. Survival differences were compared using the log-rank test. Univariable and multivariable analyses were conducted using the Cox proportional hazards model.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of a total of 1016 patients, 806 (497 men [61.7%]; median [IQR] age, 69 [64-76] years) were eligible for electronic computed tomography image analysis. The median (IQR) duration of follow-up for survival was 5.2 (3.6-6.4) years. Respiratory strength was more closely correlated with PMI than pectoralis muscle radiodensity (Pearson r2, 0.58 vs 0.29). Respiratory strength and PMI declined with aging simultaneously (both P for trend &lt; .001). Pre-respiratory sarcopenia was present in 177 patients (22.0%), and respiratory sarcopenia was present in 130 patients (16.1%). The risk of postoperative complications escalated from 82 patients (16.4%) with normal status to 39 patients (22.0%) with pre-respiratory sarcopenia to 39 patients (30.0%) with respiratory sarcopenia (P for trend &lt; .001), as did the risk of delayed recovery after surgery (P for trend &lt; .001). Compared with patients with normal status or pre-respiratory sarcopenia, patients with respiratory sarcopenia exhibited worse 5-year overall survival (438 patients [87.2%] vs 133 patients [72.9%] vs 85 patients [62.5%]; P for trend &lt; .001). Multivariable analysis identified respiratory sarcopenia as a factor independently associated with increased risk of mortality (hazard ratio, 1.83; 95% CI, 1.15-2.89; P = .01) after adjustment for sex, age, smoking status, performance ","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":"66-73"},"PeriodicalIF":15.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time Since Prior NSTEMI and Major Adverse Cardiovascular and Cerebrovascular Events After Noncardiac Surgery. 既往 NSTEMI 与非心脏手术后重大心脑血管不良事件的发生时间。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2025-01-01 DOI: 10.1001/jamasurg.2024.4683
Laurent G Glance, Karen E Joynt Maddox, Sabu Thomas, Mark J Sorbero, Lee A Fleisher, Stewart J Lustik, Heather L Lander, Jingjing Shang, Patricia W Stone, Michael P Eaton, Marjorie S Gloff, Andrew W Dick
<p><strong>Importance: </strong>Delaying elective noncardiac surgery after a recent acute myocardial infarction is associated with better outcomes, but current American Heart Association recommendations are based on data that are more than 20 years old.</p><p><strong>Objective: </strong>To examine the association between the time since a non-ST-segment elevation myocardial infarction (NSTEMI) and the risk of postoperative major adverse cardiovascular and cerebrovascular events (MACCE).</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study examined Medicare claims data between 2015 and 2020 for patients 67 years or older who had major noncardiac surgery. Data were analyzed from September 21, 2023, to February 1, 2024.</p><p><strong>Exposure: </strong>Time elapsed between a prior NSTEMI and surgery.</p><p><strong>Main outcomes and measures: </strong>MACCE (30-day mortality, in-hospital myocardial infarction, heart failure, or stroke) and all-cause 30-day mortality. Multivariable logistic regression was used to estimate the association between outcomes and time since a prior NSTEMI.</p><p><strong>Results: </strong>The sample included 5 227 473 surgeries. The mean (SD) age was 75.7 (6.6) years; 2 981 239 (57.0%) were female, and 2 246 234 (43%) were male. There were 42 278 patients (0.81%) with a previous NSTEMI. Compared with patients without a prior NSTEMI, patients with an NSTEMI within 30 days of elective surgery had higher odds of MACCE, regardless of whether they had undergone coronary revascularization (adjusted odds ratio [aOR], 2.15; 95% CI, 1.09-4.23; P = .03) or not (aOR, 2.04; 95% CI, 1.31-3.16; P = .001). The odds of postoperative MACCE leveled off after 30 days in patients who had undergone any coronary revascularization procedure (and after 90 days in patients with drug-eluting stents) and then increased after 180 days (any revascularization at 181-365 days: aOR, 1.46; 95% CI, 1.25-1.71; P < .001; patients with drug-eluting stents at 181-365 days: aOR, 1.73; 95% CI, 1.42-2.12; P < .001). The odds of MACCE did not level off for patients who did not have revascularization. Findings for all-cause 30-day mortality were similar to those for MACCE, except that the odds of mortality in patients with previous NSTEMI who had revascularization leveled off after 60 days in elective surgeries and 90 days for nonelective surgeries (elective 30-day: aOR, 2.88; 95% CI, 1.30-6.36; P = .009; elective 61- to 90-day: aOR, 1.03; 95% CI, 0.57-1.86; P = .92; nonelective 30-day: aOR, 1.91; 95% CI, 1.52-2.40; P < .001; nonelective 91- to 120-day: aOR, 1.00; 95% CI, 0.73-1.37; P = .99).</p><p><strong>Conclusions and relevance: </strong>This study found that among older patients undergoing noncardiac surgery who had revascularization, the odds of postoperative MACCE and mortality leveled off between 30 and 90 days and then increased after 180 days. The odds did not level off for patients who did not have revascularization. Delayin
重要性:在最近发生急性心肌梗死后推迟择期非心脏手术与更好的预后有关,但美国心脏协会目前的建议是基于20多年前的数据:目的:研究非 ST 段抬高型心肌梗死(NSTEMI)发生后的时间与术后主要不良心脑血管事件(MACCE)风险之间的关系:这项横断面研究检查了 2015 年至 2020 年期间 67 岁或以上接受过非心脏大手术患者的医疗保险报销数据。数据分析时间为 2023 年 9 月 21 日至 2024 年 2 月 1 日。暴露:既往 NSTEMI 与手术之间的时间间隔:MACCE(30 天死亡率、院内心肌梗死、心力衰竭或中风)和全因 30 天死亡率。采用多变量逻辑回归估计结果与既往NSTEMI发生时间之间的关系:样本包括 5 227 473 例手术。平均(标清)年龄为 75.7(6.6)岁;女性 2 981 239 人(57.0%),男性 2 246 234 人(43%)。42 278 名患者(0.81%)曾患过 NSTEMI。与既往未患 NSTEMI 的患者相比,在择期手术后 30 天内患 NSTEMI 的患者无论是否接受过冠状动脉血运重建,发生 MACCE 的几率都更高(调整后的几率比 [aOR],2.15;95% CI,1.09-4.23;P = .03)(aOR,2.04;95% CI,1.31-3.16;P = .001)。接受过任何冠状动脉血运重建手术的患者术后发生 MACCE 的几率在 30 天后趋于平稳(使用药物洗脱支架的患者在 90 天后趋于平稳),在 180 天后有所上升(181-365 天接受过任何血运重建手术:aOR,1.46;95% CI,1.25-1.71;P 结论及意义:本研究发现,在接受非心脏手术并进行血管重建的老年患者中,术后 MACCE 和死亡率的几率在 30 到 90 天之间趋于平稳,然后在 180 天后上升。而未接受血管重建手术的患者的几率并没有趋于平稳。对于接受过血管重建手术的患者来说,将择期非心脏手术推迟到 NSTEMI 后 90 天到 180 天之间可能是合理的。
{"title":"Time Since Prior NSTEMI and Major Adverse Cardiovascular and Cerebrovascular Events After Noncardiac Surgery.","authors":"Laurent G Glance, Karen E Joynt Maddox, Sabu Thomas, Mark J Sorbero, Lee A Fleisher, Stewart J Lustik, Heather L Lander, Jingjing Shang, Patricia W Stone, Michael P Eaton, Marjorie S Gloff, Andrew W Dick","doi":"10.1001/jamasurg.2024.4683","DOIUrl":"10.1001/jamasurg.2024.4683","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Delaying elective noncardiac surgery after a recent acute myocardial infarction is associated with better outcomes, but current American Heart Association recommendations are based on data that are more than 20 years old.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To examine the association between the time since a non-ST-segment elevation myocardial infarction (NSTEMI) and the risk of postoperative major adverse cardiovascular and cerebrovascular events (MACCE).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This cross-sectional study examined Medicare claims data between 2015 and 2020 for patients 67 years or older who had major noncardiac surgery. Data were analyzed from September 21, 2023, to February 1, 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposure: &lt;/strong&gt;Time elapsed between a prior NSTEMI and surgery.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;MACCE (30-day mortality, in-hospital myocardial infarction, heart failure, or stroke) and all-cause 30-day mortality. Multivariable logistic regression was used to estimate the association between outcomes and time since a prior NSTEMI.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The sample included 5 227 473 surgeries. The mean (SD) age was 75.7 (6.6) years; 2 981 239 (57.0%) were female, and 2 246 234 (43%) were male. There were 42 278 patients (0.81%) with a previous NSTEMI. Compared with patients without a prior NSTEMI, patients with an NSTEMI within 30 days of elective surgery had higher odds of MACCE, regardless of whether they had undergone coronary revascularization (adjusted odds ratio [aOR], 2.15; 95% CI, 1.09-4.23; P = .03) or not (aOR, 2.04; 95% CI, 1.31-3.16; P = .001). The odds of postoperative MACCE leveled off after 30 days in patients who had undergone any coronary revascularization procedure (and after 90 days in patients with drug-eluting stents) and then increased after 180 days (any revascularization at 181-365 days: aOR, 1.46; 95% CI, 1.25-1.71; P &lt; .001; patients with drug-eluting stents at 181-365 days: aOR, 1.73; 95% CI, 1.42-2.12; P &lt; .001). The odds of MACCE did not level off for patients who did not have revascularization. Findings for all-cause 30-day mortality were similar to those for MACCE, except that the odds of mortality in patients with previous NSTEMI who had revascularization leveled off after 60 days in elective surgeries and 90 days for nonelective surgeries (elective 30-day: aOR, 2.88; 95% CI, 1.30-6.36; P = .009; elective 61- to 90-day: aOR, 1.03; 95% CI, 0.57-1.86; P = .92; nonelective 30-day: aOR, 1.91; 95% CI, 1.52-2.40; P &lt; .001; nonelective 91- to 120-day: aOR, 1.00; 95% CI, 0.73-1.37; P = .99).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;This study found that among older patients undergoing noncardiac surgery who had revascularization, the odds of postoperative MACCE and mortality leveled off between 30 and 90 days and then increased after 180 days. The odds did not level off for patients who did not have revascularization. Delayin","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":"45-54"},"PeriodicalIF":15.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Error in Figure. 图中错误。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2025-01-01 DOI: 10.1001/jamasurg.2024.5361
{"title":"Error in Figure.","authors":"","doi":"10.1001/jamasurg.2024.5361","DOIUrl":"10.1001/jamasurg.2024.5361","url":null,"abstract":"","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":"115"},"PeriodicalIF":15.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Error in Author Affiliation and Name. 作者所属单位和名称错误。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2025-01-01 DOI: 10.1001/jamasurg.2024.6210
{"title":"Error in Author Affiliation and Name.","authors":"","doi":"10.1001/jamasurg.2024.6210","DOIUrl":"https://doi.org/10.1001/jamasurg.2024.6210","url":null,"abstract":"","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":"160 1","pages":"115"},"PeriodicalIF":15.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anterior Gastropexy for Paraesophageal Hernia Repair: A Randomized Clinical Trial. 胃前固定术治疗食管旁疝:一项随机临床试验。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2024-12-23 DOI: 10.1001/jamasurg.2024.5788
Clayton C Petro, Ryan C Ellis, Sara M Maskal, Sam J Zolin, Chao Tu, Adele Costanzo, Lucas R A Beffa, David M Krpata, Diya Alaedeen, Ajita S Prabhu, Benjamin T Miller, Kevin F Baier, Alisan Fathalizadeh, John Rodriguez, Michael J Rosen
<p><strong>Importance: </strong>Paraesophageal hernias can cause severe limitations in quality of life and life-threatening complications. Even though minimally invasive paraesophageal hernia repair (MIS-PEHR) is safe and effective, anatomic recurrence rates remain notoriously high. Retrospective data suggest that suturing the stomach to the anterior abdominal wall after repair-an anterior gastropexy-may reduce recurrence, but this adjunct is currently not the standard of care.</p><p><strong>Objective: </strong>To determine whether anterior gastropexy reduces 1-year recurrence after MIS-PEHR.</p><p><strong>Design, setting, and participants: </strong>This registry-based randomized clinical trial was conducted by 10 surgeons at 3 academic hospitals within the Cleveland Clinic Enterprise. Between June 26, 2019, and July 24, 2023, 348 patients were assessed for eligibility, and 240 patients were enrolled and randomized. Statistical analysis was performed from January to March 2024.</p><p><strong>Intervention: </strong>Enrolled patients were randomized to and received either an anterior gastropexy (n = 119) or no anterior gastropexy (n = 121).</p><p><strong>Main outcome: </strong>The primary outcome was recurrence as determined by reherniation of the stomach greater than 2 cm above the diaphragm on routine imaging at 1 year or reoperation. Secondary outcomes included quality of life as measured by the Gastroesophageal Reflux Health-Related Quality of Life survey, additional foregut symptom questionnaire, and patient satisfaction at 30 days and 1 year.</p><p><strong>Results: </strong>A total of 240 patients were randomized to either anterior gastropexy (n = 119; 104 [97%] women; median [IQR] age, 70 [64-75] years) or no anterior gastropexy (n = 121; 97 [80%] women; median [IQR] age, 68 [62-73] years) at the end of their MIS-PEHR. At 1 year, 188 patients (78%) had completed follow-up. By intention-to-treat analysis, 1-year recurrence was significantly lower in patients who received an anterior gastropexy (15% vs 36%; risk difference, 0.21 [95% CI, 0.09-0.33]), which remained significant after risk-adjusted regression analysis (hazard ratio, 0.38 [95% CI, 0.23-0.60]). Of 13 reoperations (5.4%) for recurrence in the first year, 3 (2.5%) were in the anterior gastropexy group and 10 (8.2%) were in the no-gastropexy group (P = .052). Two patients (1.7%) had their anterior gastropexy sutures removed for pain. There were no significant differences in quality-of-life outcomes at 30 days and 1 year between treatment groups.</p><p><strong>Conclusions and relevance: </strong>This randomized clinical trial found that the addition of an anterior gastropexy to MIS-PEHR is superior to no gastropexy in regard to reducing 1-year paraesophageal hernia recurrence. These results suggest that an anterior gastropexy should be routinely used in the context of minimally invasive paraesophageal hernia repair.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identif
重要性:食道旁疝可导致严重的生活质量限制和危及生命的并发症。尽管微创食管旁疝修补术(MIS-PEHR)是安全有效的,但解剖复发率仍然很高。回顾性数据显示,胃修复后将胃缝合到前腹壁(胃前固定术)可能会减少复发,但这种辅助方法目前还不是标准的治疗方法。目的:确定胃前路固定术是否能减少miss - pehr术后1年的复发。设计、环境和参与者:这项基于注册的随机临床试验由克利夫兰诊所企业内3家学术医院的10名外科医生进行。在2019年6月26日至2023年7月24日期间,对348名患者进行了资格评估,其中240名患者入组并随机分组。统计分析时间为2024年1 - 3月。干预:纳入的患者随机分为两组,分别接受胃前固定术(n = 119)和不接受胃前固定术(n = 121)。主要预后:主要预后为复发,1年常规影像学检查胃再疝大于膈肌2cm或再次手术。次要结局包括通过胃食管反流健康相关生活质量调查测量的生活质量,额外的前肠症状问卷,以及30天和1年的患者满意度。结果:共有240例患者被随机分配到胃前固定术组(n = 119;104名(97%)女性;中位[IQR]年龄,70[64-75]岁)或没有胃前固定术(n = 121;女性97人(80%);MIS-PEHR结束时的中位[IQR]年龄为68岁[62-73]岁。1年时,188例患者(78%)完成了随访。意向治疗分析显示,接受前胃固定术的患者1年复发率显著降低(15% vs 36%;风险差异,0.21 [95% CI, 0.09-0.33]),经风险调整回归分析后仍然显著(风险比,0.38 [95% CI, 0.23-0.60])。第一年复发再手术13例(5.4%),胃前固定术组3例(2.5%),无胃固定术组10例(8.2%)(P = 0.052)。2例(1.7%)患者因疼痛切除胃前固定术缝合线。治疗组之间30天和1年的生活质量结果无显著差异。结论和相关性:这项随机临床试验发现,在减少1年食道旁疝复发方面,在miss - pehr中增加胃前固定术优于不进行胃前固定术。这些结果表明,胃前固定术应常规应用于微创食管旁疝修复。试验注册:ClinicalTrials.gov标识符:NCT04007952。
{"title":"Anterior Gastropexy for Paraesophageal Hernia Repair: A Randomized Clinical Trial.","authors":"Clayton C Petro, Ryan C Ellis, Sara M Maskal, Sam J Zolin, Chao Tu, Adele Costanzo, Lucas R A Beffa, David M Krpata, Diya Alaedeen, Ajita S Prabhu, Benjamin T Miller, Kevin F Baier, Alisan Fathalizadeh, John Rodriguez, Michael J Rosen","doi":"10.1001/jamasurg.2024.5788","DOIUrl":"https://doi.org/10.1001/jamasurg.2024.5788","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Paraesophageal hernias can cause severe limitations in quality of life and life-threatening complications. Even though minimally invasive paraesophageal hernia repair (MIS-PEHR) is safe and effective, anatomic recurrence rates remain notoriously high. Retrospective data suggest that suturing the stomach to the anterior abdominal wall after repair-an anterior gastropexy-may reduce recurrence, but this adjunct is currently not the standard of care.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To determine whether anterior gastropexy reduces 1-year recurrence after MIS-PEHR.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This registry-based randomized clinical trial was conducted by 10 surgeons at 3 academic hospitals within the Cleveland Clinic Enterprise. Between June 26, 2019, and July 24, 2023, 348 patients were assessed for eligibility, and 240 patients were enrolled and randomized. Statistical analysis was performed from January to March 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Intervention: &lt;/strong&gt;Enrolled patients were randomized to and received either an anterior gastropexy (n = 119) or no anterior gastropexy (n = 121).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcome: &lt;/strong&gt;The primary outcome was recurrence as determined by reherniation of the stomach greater than 2 cm above the diaphragm on routine imaging at 1 year or reoperation. Secondary outcomes included quality of life as measured by the Gastroesophageal Reflux Health-Related Quality of Life survey, additional foregut symptom questionnaire, and patient satisfaction at 30 days and 1 year.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 240 patients were randomized to either anterior gastropexy (n = 119; 104 [97%] women; median [IQR] age, 70 [64-75] years) or no anterior gastropexy (n = 121; 97 [80%] women; median [IQR] age, 68 [62-73] years) at the end of their MIS-PEHR. At 1 year, 188 patients (78%) had completed follow-up. By intention-to-treat analysis, 1-year recurrence was significantly lower in patients who received an anterior gastropexy (15% vs 36%; risk difference, 0.21 [95% CI, 0.09-0.33]), which remained significant after risk-adjusted regression analysis (hazard ratio, 0.38 [95% CI, 0.23-0.60]). Of 13 reoperations (5.4%) for recurrence in the first year, 3 (2.5%) were in the anterior gastropexy group and 10 (8.2%) were in the no-gastropexy group (P = .052). Two patients (1.7%) had their anterior gastropexy sutures removed for pain. There were no significant differences in quality-of-life outcomes at 30 days and 1 year between treatment groups.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;This randomized clinical trial found that the addition of an anterior gastropexy to MIS-PEHR is superior to no gastropexy in regard to reducing 1-year paraesophageal hernia recurrence. These results suggest that an anterior gastropexy should be routinely used in the context of minimally invasive paraesophageal hernia repair.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Trial registration: &lt;/strong&gt;ClinicalTrials.gov Identif","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":""},"PeriodicalIF":15.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frailty and Long-Term Health Care Utilization After Elective General and Vascular Surgery. 择期普通手术和血管手术后的虚弱和长期保健利用。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2024-12-23 DOI: 10.1001/jamasurg.2024.5711
Shernaz S Dossabhoy, Laura A Graham, Aditi Kashikar, Elizabeth L George, Carolyn D Seib, Manjula Kurella Tamura, Todd H Wagner, Mary T Hawn, Shipra Arya
<p><strong>Importance: </strong>Surgical quality improvement efforts have largely focused on 30-day outcomes, such as readmissions and complications. Surgery may have a sustained impact on the health and quality of life of patients considered frail, yet data are lacking on the long-term health care utilization of patients with frailty following surgery.</p><p><strong>Objective: </strong>To examine the independent association of preoperative frailty on long-term health care utilization (up to 24 months) following surgery.</p><p><strong>Design, setting, and participants: </strong>This retrospective, observational cohort study included patients undergoing elective general and vascular surgery performed in the Veterans Affairs (VA) Surgical Quality Improvement Program with study entry from October 1, 2013, to September 30, 2018. Patients were followed up for 24 months. Patients with nursing home visits prior to surgery, emergent cases, and in-hospital deaths were excluded. Data analysis was conducted from September 2022 to May 2024.</p><p><strong>Exposures: </strong>Preoperative frailty as assessed by the Risk Analysis Index (RAI-A) score: robust, less than 20; normal, 20 to 29; frail, 30 to 39; and very frail, 40 or more.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was health care utilization through 24 months, defined as inpatient admissions, outpatient visits, emergency department (ED) visits, and nursing home or rehabilitation services collected via Corporate Data Warehouse and Centers for Medicare & Medicaid Services data. χ2 Tests and analysis of variance were used to assess preoperative frailty status, and a Cox proportional hazards model was used to calculate the adjusted association of preoperative frailty on each postdischarge health care utilization outcome.</p><p><strong>Results: </strong>This study identified 183 343 elective general (80.5%) and vascular (19.5%) procedures (mean [SD] age, 62 [12.7] years; 12 915 females [7.0%]; 28 671 Black patients [16.0]; 138 323 White patients [77.3%]; 94 451 Medicare enrollees [51.5%]) with mean (SD) RAI-A score of 22.2 (7.0). After adjustment for baseline characteristics and preoperative use of health care services, frailty was associated with higher inpatient admissions (frail: hazard ratio [HR], 1.75; 95% CI, 1.70-1.79; very frail: HR, 2.33; 95% CI, 2.25-2.42), ED visits (frail: HR, 1.39; 95% CI, 1.36-1.41; very frail: HR, 1.70; 95% CI, 1.65-1.75), and nursing home or rehabilitation encounters (frail: HR, 4.97; 95% CI, 4.36-5.67; very frail: HR, 7.44; 95% CI, 6.34-8.73). For patients considered frail and very frail, health care utilization was higher after surgery and remained significant through 24 months for all outcomes (using piecewise Cox proportional hazards modeling).</p><p><strong>Conclusions and relevance: </strong>In this study, frailty was a significant risk factor for high long-term health care utilization after surgery. This may have quality of life implicat
重要性:手术质量改善的努力主要集中在30天的结果,如再入院和并发症。手术可能对体弱多病患者的健康和生活质量产生持续影响,但缺乏手术后体弱多病患者长期医疗保健利用的数据。目的:探讨术前虚弱与术后长期医疗保健利用(长达24个月)的独立关系。设计、环境和参与者:这项回顾性、观察性队列研究纳入了2013年10月1日至2018年9月30日在退伍军人事务部(VA)手术质量改进计划中接受选择性全身和血管手术的患者。随访24个月。排除手术前到疗养院就诊的患者、急诊病例和院内死亡病例。数据分析时间为2022年9月至2024年5月。风险分析指数(RAI-A)评分评估的术前虚弱:稳健,小于20;正常,20 - 29岁;体弱多病,30至39岁;而且非常虚弱,40岁以上。主要结局和测量:主要结局是24个月的医疗保健利用情况,定义为住院患者入院、门诊就诊、急诊科(ED)就诊、疗养院或康复服务,这些数据通过企业数据仓库和医疗保险和医疗补助服务中心收集。采用χ2检验和方差分析评估术前虚弱状况,采用Cox比例风险模型计算术前虚弱与各出院后医疗保健利用结果的校正相关性。结果:该研究确定了183例 343例选择性一般手术(80.5%)和血管手术(19.5%)(平均[SD]年龄62[12.7]岁;12 雌性915例[7.0%];黑人28671例[16.0];138例 白人323例[77.3%];94 451名医疗保险参保人[51.5%]),平均(SD) raa评分为22.2(7.0)。在调整基线特征和术前使用卫生保健服务后,虚弱与较高的住院率相关(虚弱:危险比[HR], 1.75;95% ci, 1.70-1.79;非常虚弱:HR 2.33;95% CI, 2.25-2.42),急诊科就诊(体弱:HR, 1.39;95% ci, 1.36-1.41;非常虚弱:HR, 1.70;95% CI, 1.65-1.75),以及疗养院或康复中心(体弱:HR, 4.97;95% ci, 4.36-5.67;非常虚弱:HR, 7.44;95% ci, 6.34-8.73)。对于被认为虚弱和非常虚弱的患者,手术后的医疗保健利用率更高,并且在24个月内所有结果都保持显著(使用分段Cox比例风险模型)。结论和相关性:在本研究中,虚弱是术后长期医疗保健使用率高的重要危险因素。这可能对患者的生活质量产生影响,对卫生保健系统和支付方的政策产生影响。
{"title":"Frailty and Long-Term Health Care Utilization After Elective General and Vascular Surgery.","authors":"Shernaz S Dossabhoy, Laura A Graham, Aditi Kashikar, Elizabeth L George, Carolyn D Seib, Manjula Kurella Tamura, Todd H Wagner, Mary T Hawn, Shipra Arya","doi":"10.1001/jamasurg.2024.5711","DOIUrl":"https://doi.org/10.1001/jamasurg.2024.5711","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Surgical quality improvement efforts have largely focused on 30-day outcomes, such as readmissions and complications. Surgery may have a sustained impact on the health and quality of life of patients considered frail, yet data are lacking on the long-term health care utilization of patients with frailty following surgery.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To examine the independent association of preoperative frailty on long-term health care utilization (up to 24 months) following surgery.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This retrospective, observational cohort study included patients undergoing elective general and vascular surgery performed in the Veterans Affairs (VA) Surgical Quality Improvement Program with study entry from October 1, 2013, to September 30, 2018. Patients were followed up for 24 months. Patients with nursing home visits prior to surgery, emergent cases, and in-hospital deaths were excluded. Data analysis was conducted from September 2022 to May 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposures: &lt;/strong&gt;Preoperative frailty as assessed by the Risk Analysis Index (RAI-A) score: robust, less than 20; normal, 20 to 29; frail, 30 to 39; and very frail, 40 or more.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The primary outcome was health care utilization through 24 months, defined as inpatient admissions, outpatient visits, emergency department (ED) visits, and nursing home or rehabilitation services collected via Corporate Data Warehouse and Centers for Medicare & Medicaid Services data. χ2 Tests and analysis of variance were used to assess preoperative frailty status, and a Cox proportional hazards model was used to calculate the adjusted association of preoperative frailty on each postdischarge health care utilization outcome.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;This study identified 183 343 elective general (80.5%) and vascular (19.5%) procedures (mean [SD] age, 62 [12.7] years; 12 915 females [7.0%]; 28 671 Black patients [16.0]; 138 323 White patients [77.3%]; 94 451 Medicare enrollees [51.5%]) with mean (SD) RAI-A score of 22.2 (7.0). After adjustment for baseline characteristics and preoperative use of health care services, frailty was associated with higher inpatient admissions (frail: hazard ratio [HR], 1.75; 95% CI, 1.70-1.79; very frail: HR, 2.33; 95% CI, 2.25-2.42), ED visits (frail: HR, 1.39; 95% CI, 1.36-1.41; very frail: HR, 1.70; 95% CI, 1.65-1.75), and nursing home or rehabilitation encounters (frail: HR, 4.97; 95% CI, 4.36-5.67; very frail: HR, 7.44; 95% CI, 6.34-8.73). For patients considered frail and very frail, health care utilization was higher after surgery and remained significant through 24 months for all outcomes (using piecewise Cox proportional hazards modeling).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;In this study, frailty was a significant risk factor for high long-term health care utilization after surgery. This may have quality of life implicat","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":""},"PeriodicalIF":15.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Investigational Device Exemption Effect-More Than Just Volume. 调查器械豁免效应——不仅仅是数量。
IF 15.7 1区 医学 Q1 SURGERY Pub Date : 2024-12-23 DOI: 10.1001/jamasurg.2024.5664
Juliet Blakeslee Carter, Adam W Beck
{"title":"The Investigational Device Exemption Effect-More Than Just Volume.","authors":"Juliet Blakeslee Carter, Adam W Beck","doi":"10.1001/jamasurg.2024.5664","DOIUrl":"https://doi.org/10.1001/jamasurg.2024.5664","url":null,"abstract":"","PeriodicalId":14690,"journal":{"name":"JAMA surgery","volume":" ","pages":""},"PeriodicalIF":15.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAMA surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1